A Phase 2 Study of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With Hemophilia
Condition(s) studied
Investigational drug(s) / intervention(s)
Foscenvivint: Experimental:Foscenvivint Administered by intravenous (IV) infusion over 3-4 hours Arm Description:Foscenvivint 280 mg/m2, once a week for 24 weeks
Study summary
This is a phase 2 study to evaluate the efficacy and safety of foscenvivint in patients with liver cirrhosis resulting from HIV/HCV co-infection in the setting of hemophilia.
Eligibility
Primary outcome measure(s)
- ALBI score — Baseline to 24 weeks after administration
Change from baseline in ALBI score at 24 weeks after administration. ALBI score = (log10 bilirubin \[mg/dL\] x 17.1) x 0.66 + (albumin \[g/dL\] x 10 x -0.085)
Trial sites (4)
| Facility | City | Region | Status |
|---|---|---|---|
| Hokkaido University Hospital | Sapporo | Hokkaido | Recruiting |
| National Hospital Organization Sendai Medical Center | Sendai | Miyagi | Recruiting |
| National Hospital Organization Osaka National Hospital | Osaka | Osaka | Recruiting |
| Tokyo Metropolitan Komagome Hospital | Bunkyo-Ku | Tokyo | Recruiting |
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07681089 on ClinicalTrials.gov ↗ ← All trials in Japan